Based on the FIREFLY-1 data, would you consider using tovorafenib monotherapy front-line in pediatric patients who have low grade gliomas that are only amenable to subtotal resection or are unresectable?

Not yet. I think it is important to wait for the results of FIREFLY-2 and also ACNS1831/ACNS1833. We have to keep in mind that the combination of trametinib and dabrafenib is already FDA-approved as frontline treatment for paediatric patients with BRAF V600 mutated LGG. This approval was based on th...

No. The FIREFLY-1 data supports the use of tovorafenib for the treatment of patients with recurrent or refractory disease. The results of the ongoing FIREFLY-2 trial which randomizes newly diagnosed patients to front-line therapy with either standard-of-care chemotherapy or tovorafenib therapy will ...